Adoptive therapy of cytomegalovirus-specific T lymphocytes: Is less more?

Clinical Infectious Diseases

Volumn 52, Issue 1, 2011, Pages 58-60

  Perales, Miguel Angel ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; HLA ANTIGEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; EPSTEIN BARR VIRUS; GRAFT VERSUS HOST REACTION; NOTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RISK FACTOR; T CELL DEPLETION; T LYMPHOCYTE; VIRUS REACTIVATION; ADOPTIVE IMMUNOTHERAPY; HUMAN; IMMUNOLOGY; METHODOLOGY; TREATMENT OUTCOME;

CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 79951627276     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq055     Document Type: Note

References (29)

1. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 2010;24(2):319-337.
2. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003;102(13):4255-4260. (Pubitemid 37494081)
3. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004;103(6):2003-2008. (Pubitemid 38326213)
4. Matsumura T, Narimatsu H, Kami M, et al. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients. Biol Blood Marrow Transplant 2007;13(5):577-583. (Pubitemid 46585928)
5. George B, Pati N, Gilroy N, et al. Pretransplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis 2010;12(4):322-329.
6. Lamba R, Carrum G, Myers GD, et al. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant 2005;36(9):797-802. (Pubitemid 41613303)
7. van Burik JA, Carter SL, Freifeld AG, et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T celldepleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant 2007;13(12):1487-1498. (Pubitemid 350091387)
8. Delgado J, Pillai S, Benjamin R, et al. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2008;14(11):1288-1297.
9. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991;78(5):1373-1380.
10. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994;83(7):1971-1979. (Pubitemid 24107924)
11. Reusser P, Attenhofer R, Hebart H, Helg C, Chapuis B, Einsele H. Cytomegalovirusspecific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants. Blood 1997;89(10):3873-3879. (Pubitemid 27227114)
12. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003 15; 101(2):407-414. (Pubitemid 36077556)
13. Peggs KS. Adoptive T cell immunotherapy for cytomegalovirus. Expert Opin Biol Ther 2009;9(6):725-736.
14. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257(5067):238-241.
15. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333(16):1038-1044.
16. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005;202(3):379-386. (Pubitemid 41126955)
17. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99(11):3916-3922. (Pubitemid 35332029)
18. Peggs K, Verfuerth S, Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood 2001;97(4):994-1000. (Pubitemid 32154284)
19. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stemcell transplantation with virus-specific T-cell lines. Lancet 2003;362(9393):1375-1377. (Pubitemid 37338339)
20. Peggs KS, Verfuerth S, Pizzey A, Chow SL, Thomson K, Mackinnon S. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis 2009;49(12):1851-1860.
21. Mackinnon S, Thomson K, Verfuerth S, Peggs K, Lowdell M. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis 2008;40(1):63-67. (Pubitemid 350192302)
22. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006;12(10):1160-1166. (Pubitemid 44527351)
23. Micklethwaite KP, Clancy L, Sandher U, et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008;112(10):3974-3981.
24. Trivedi D, Williams RY, O'Reilly RJ, Koehne G. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood 2005;105(7):2793-8201.
25. Koehne G, Doubrovina E, Hasan A, et al. A phase I dose escalation trial of donor T Cells sensitized with pentadecapeptides of the CMV-pp65 protein for the treatment of CMV infections following allogeneic hematopoietic stem cell transplants. Blood 2009;114:2262.
26. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007;110(4):1123-1131. (Pubitemid 47281407)
27. Barker JN, Doubrovina E, Sauter C, et al. Successful treatment of Epstein-Barr virus (EBV)-associated post-transplant lymphoma after cord blood transplant using third-party EBV-specific cytotoxic T-lymphocytes. Blood 2010 [Epub ahead of print].
28. Peggs KS, Thomson K, Samuel E, et al. Directly selected cytomegalorivus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011;52:49-57.
29. Hanley PJ, Cruz CR, Savoldo B, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009;114(9):1958-1967.